FDA approves drug to treat all types of diabetes

11:21 p.m.

Wednesday, November 28, 2018

CAIRE –

The US Food and Drug Administration (FDA) has approved the world's first drug for treating any type of cancer from its source, which is good news for all patients.

This makes it a "good news" for all cancer patients: the new drug is designed for adults and children. He calls himself Vitrakvi.

The new drug, according to the Russian agency "Sputnik", the treatment of genetic mutations of tumors, regardless of the type of disease or place of origin.

The agency "NBC News", the US Commissioner to the Commission, Scott Jotlib, said: "The ratification of the authorization and the release of this drug, an important step in the treatment of cancer, because it is treated at the source and treats the base of cancerous tumors, regardless of the place of origin in the human body. "

Gottlieb said the new drug will help cancer patients finally get the right treatment at the right time.

VITRAKFI will help treat people with different cancers, but has common genetic mutations.

"Traditionally, the cancer was treated according to the source of the tumor, that is to say that it affected any part of the body, but the treatment will now be n?" anywhere in the body because you are treating it, "said David Hayman, president of the Center for Early Drug Development at the New York-based Memorandum Sloan Kettering Cancer Center. The original gene at the origin of the appearance of the tumor ".

The drug was tested on Anna Plaza and her daughter Rihanna last year after Anna had a cancerous tumor and her daughter Rihanna Burm was born with cancer on her arm.

Vitrakvi was administered to the newborn every day. Scientists were surprised to find that the tumor had begun to contract in just 3 days.

The drug will be given to two bodies, the first in the form of tablets or capsules and the other in the form of children's drug syrup in particular.

But until now, the drug remains very expensive, the program costing more than $ 393,000 a year, while its cost per month will cost about $ 11,000.